Global **Malaria** Programme

Report on antimalarial drug efficacy, resistance and response

years of surveillance (2010–2019)

World Health Organization

Global **Malaria** Programme

Report on antimalarial drug efficacy, resistance and response



years of surveillance (2010–2019)

World Health Organization

Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019)

ISBN 978-92-4-001281-3 (electronic version)
ISBN 978-92-4-001282-0 (print version)

Suggested citation. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Layout by Lushomo, South Africa

Contents

ACKNOWLEDGEMENTS

This document was prepared for the World Health Organization (WHO) Global Malaria Programme (GMP) by Charlotte Rasmussen and Pascal Ringwald, with the support of Amy Barrette and Lucia Fernandez Montoya (for the management of the database and the threats maps). WHO/GMP wishes to thank Kevin Baird, Leonardo Kishi Basco, Maria Dorina Bustos, Laurence Slutsker and Mariam Warsame for their deep review of the document and helpful suggestions. WHO/GMP also acknowledges the comments made by the regional advisors and colleagues from the regions: Elisabeth Juma, Akpaka Kalu, James Kelly, Roberto Montoya, Spes Caritas Ntabangana, Risintha Gayan Premaratne, Abderahmane Kharchi Tfeil, Maria de la Paz Ade y Torrent, Neena Nee Kesar Valecha and Ghasem Zamani. WHO/GMP wishes to thank the ministries of health, nongovernmental organizations, pharmaceutical companies, public private partnerships, research institutes, collaboratives centres, subregional networks and WHO regional offices that kindly shared their data. Financial support for the preparation of this document and the database was provided by the Bill & Melinda Gates Foundation. The final draft was edited by Cadman Editing Services, Australia.

ABBREVIATIONS AND ACRONYMS

ACPR	adequate clinical and parasitological response
ACT	artemisinin-based combination therapy
AL	artemether-lumefantrine
AQ	amodiaquine
AS	artesunate
AUC	area under the plasma drug concentration curve
CQ	chloroquine
DHA	dihydroartemisinin
ETF	early treatment failure
G6PD	glucose-6-phosphate dehydrogenase
GMP	Global Malaria Programme
GMS	Greater Mekong subregion
GPARC	Global Plan for Artemisinin Resistance Containment
HIV	human immunodeficiency virus
iDES	integrated drug efficacy surveillance
IPTi	intermittent preventive treatment of infants
IPTp	intermittent preventive treatment of pregnant women
LCF	late clinical failure
LPF	late parasitological failure
MDA	mass drug administration
MQ	mefloquine
PCR	polymerase chain reaction
Pfcrt	*P. falciparum chloroquine resistance transporter*
Pfcytb	*P. falciparum cytochrome b*
Pfdhfr	*P. falciparum dihydrofolate reductase*
Pfdhps	*P. falciparum dihydropteroate synthase*
PfK13	*P. falciparum Kelch 13*
Pfmdr1	*P. falciparum multidrug resistance 1 protein*
Pfpm 2–3	*P. falciparum plasmepsin 2–3*
PPQ	piperaquine
PQ	primaquine
Pvcrt-o	*P. vivax chloroquine resistance transporter*
Pvdhfr	*P. vivax dihydrofolate reductase*
Pvdhps	*P. vivax dihydropteroate synthase*
Pvmdr1	*P. vivax multidrug resistance 1 protein*
PSA	piperaquine survival assay
PY	pyronaridine
RSA	ring-stage survival assay
SMC	seasonal malaria chemoprevention
SP	sulfadoxine-pyrimethamine
TES	therapeutic efficacy studies